The Preparation of Convencent Plasma and Recruiting of Donors during the COVID-19 Pandemic

Cover Page
Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract


Background. The pandemic of the new coronavirus infection has challenged the medical community for quickly finding and implementing effective methods of treatment. In the absence of a vaccine or specific therapy with proven effectiveness, the usage of convalescent plasma can be the one of perspective methods. An important aspect of this technology is the efficient and safe preparation of convalescent plasma. To date, in the world literature there are practically no publications about donor recruitment and the specifics of the preparation of convalescent plasma.

Purpose of the research. Presentation of the experience of organizing a workflow for recruiting donors and stockpiling of convalescent plasma with a high titer of virus-neutralizing antibodies to SARS-CoV-2.

Methods. The analysis of the work of the Blood Service of the Moscow Department of Health for stockpiling of COVID-19 convalescent plasma has been executed. In total it has been stockpiled 1240 doses. The normative documentation has been developed by a working group on the basis of the current federal legislation of Russian federation and been approved by the Moscow Department of Health. The titer of neutralizing antibodies (VNA) has been determined as the basic method for assessing the immunological viability of convalescent plasma. The main characteristics of donors, the characteristics of the disease course, the results of preliminary testing for the presence of specific antibodies by ELISA and CLIA methods has been compared with VNA titers in the stockpiled convalescent plasma.

Results. Due to a Moscow Health Department’s order No. 325 dated 01.04.2020 (a basic local regulatory document) it has been developed a regulation for the stockpiling, examination, storage, safety and transfering of fresh frozen pathogen-reduced plasma of COVID-19 convalescent donors to medical organizations of the Moscow Health Department. For arranging an interaction with donors it has been created a call-center. For effective preliminary selection, it has been formed a donor characteristics list, which has been combined with screening of specific antibodies by ELISA and CLIA methods.

Conclusions. Developed a system of recruiting donors and procurement process of convalescent plasma for treatment СOVID-19, which includes the necessary regulations, algorithms for the selection and recruitment of donors, the registry of donors and recipients, algorithms, efficiency and safety of convalescent plasma.


Full Text

Restricted Access

About the authors

Alexandr I. Kostin

N.V. Sklifosovsky Research Institute of Emergency Medicine, Moscow Department of Healthcare

Email: kostinai@sklif.mos.ru
ORCID iD: 0000-0001-7542-851X
SPIN-code: 7119-8871

Russian Federation, Moscow

MD, PhD

Sergey S. Petrikov

N.V. Sklifosovsky Research Institute of Emergency Medicine, Moscow Department of Healthcare

Email: petrikov@mail.ru
ORCID iD: 0000-0003-3292-8789

Russian Federation, Moscow

MD, PhD, Professor, Corresponding Member of the RAS

Nataliya V. Borovkova

N.V. Sklifosovsky Research Institute of Emergency Medicine, Moscow Department of Healthcare

Email: Borovkova@mail.ru
ORCID iD: 0000-0002-8897-7523
SPIN-code: 9339-2800

Russian Federation, Moscow

MD, PhD

Natal’ya V. Doronina

N.V. Sklifosovsky Research Institute of Emergency Medicine, Moscow Department of Healthcare

Email: Doronina@mail.ru
ORCID iD: 0000-0002-4242-2645

Russian Federation, Moscow

Mihail A. Godkov

N.V. Sklifosovsky Research Institute of Emergency Medicine, Moscow Department of Healthcare

Email: Godcov@mail.ru
ORCID iD: 0000-0002-0854-8076

Russian Federation, Moscow

MD, PhD

Irina B. Simarova

N.V. Sklifosovsky Research Institute of Emergency Medicine, Moscow Department of Healthcare; 52th City Clinical Hospital

Email: rirab@mail.ru
ORCID iD: 0000-0002-9042-3917

Russian Federation, Moscow; Moscow

MD

Olga A. Mayorova

Blood Center O.K. Gavrilova Moscow Department of Healthcare

Email: MOE@yandex.ru
SPIN-code: 8059-1987

Russian Federation, Moscow

MD, PhD, Professor

Kira S. Momotyuk

Blood Center O.K. Gavrilova Moscow Department of Healthcare

Email: kira.s.momotyuk@gmail.com
ORCID iD: 0000-0002-6836-8368

Russian Federation, Moscow

MD, PhD

Violetta V. Danilec

City Clinical Hospital M.P. Konchalovskiy

Email: buldoc68@mail.ru
ORCID iD: 0000-0003-4605-8315

Russian Federation, Moscow

Irina A. Yarotskaya

City Clinical Hospital M.P. Konchalovskiy

Email: yarotskayia@zdrav.mos.ru

Russian Federation, Moscow

Alexandr L. Gincburg

National Research Center of Epidemiology and Microbiology N.F. Gamaleya of the Ministry of Health of the Russian Federation

Email: info@gamaleya.org
ORCID iD: 0000-0003-1769-5059
SPIN-code: 7626-0373

Russian Federation, Moscow

PhD in Biology, Academician of the RAS

Alexey I. Hripun

Moscow Department of Healthcare

Email: info@gamaleya.org
ORCID iD: 0000-0001-6765-2837
SPIN-code: 5340-4305

Russian Federation, Moscow

MD, PhD

Denis Y. Logunov

National Research Center of Epidemiology and Microbiology N.F. Gamaleya of the Ministry of Health of the Russian Federation

Email: logunov@gamaleya.org
ORCID iD: 0000-0003-4035-6581
SPIN-code: 4000-4717

Russian Federation, Moscow

PhD in Biology, Corresponding Member of the RAS

Inna V. Dolschikova

National Research Center of Epidemiology and Microbiology N.F. Gamaleya of the Ministry of Health of the Russian Federation

Email: dolzhikova@gamaleya.org
ORCID iD: 0000-0003-2548-6142
SPIN-code: 1462-7079

Russian Federation, Moscow

PhD in Biology

Alexey I. Mazus

Moscow City AIDS Prevention and Control Center of the City Health Department

Email: mazus@mail.ru
ORCID iD: 0000-0002-4110-3941

Russian Federation, Moscow

MD, PhD

Elena Y. Vasilyeva

City Clinical Hospital I.V. Davydovsky

Email: Vasilyeva@yandex.ru
SPIN-code: 9515-1566

Russian Federation, Moscow

MD, PhD, Professor

Evgenij A. Vasin

52th City Clinical Hospital

Email: spectrum48@yandex.ru
ORCID iD: 0000-0002-1439-9476

Russian Federation, Moscow

Analyst

Vladimir V. Ganchin

Autonomous non-commercial organizations “Center of Analytical Development of the Social Sector”

Email: GanchinVV@zdrav.mos.ru
ORCID iD: 0000-0001-9138-6479
SPIN-code: 9058-7791

Russian Federation, Moscow

Evgeniy L. Nikonov

Moscow Department of Healthcare

Email: NikonovEL@mos.zdrav.ru
ORCID iD: 0000-0002-5231-711X
SPIN-code: 5618-1533

Russian Federation, Moscow

Alexey V. Pinchuk

N.V. Sklifosovsky Research Institute of Emergency Medicine, Moscow Department of Healthcare; Research Institute for Healthcare Organization and Medical Management

Email: PinchukAV@mos.zdrav.ru
ORCID iD: 0000-0001-9019-9567
SPIN-code: 8875-2456

Russian Federation, Moscow; Moscow

Andrey Y. Bulanov

52th City Clinical Hospital

Author for correspondence.
Email: buldoc68@mail.ru
ORCID iD: 0000-0001-6999-8145

Russian Federation, 3 Pehotnaya str., 123182, Moscow

MD, PhD

Mar’yana A. Lisenko

52th City Clinical Hospital

Email: gkb52@zdrav.mos.ru
ORCID iD: 0000-0001-6010-7975

Russian Federation, Moscow

MD, PhD

References

  1. Zhu N, Zhang D, Wang W, et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med. 2020;382(8):727–733 doi: https://doi.org/10.1056/NEJMoa2001017
  2. Wu F, Zhao S, Yu B, et al. A new coronavirus associated with human respiratory disease in China. Nature. 2020;579(7798):265–269. doi: https://doi.org/10.1038/s41586-020-2008-3
  3. Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579(7798):270–273. doi: https://doi.org/10.1038/s41586-020-2012-7
  4. Baud D, Qi X, Nielsen-Saines K, et al. Real estimates of mortality following COVID-19 infection. Lancet Infect. Dis. 2020;20(7):773. doi: https://doi.org/10/1016/S1473-3099(20)30195-X
  5. Pei S, Yuan X, Zhang ZZ, et al. Convalescent Plasma to Treat COVID-19: Chinese Strategy and Experiences. Med Rxiv. 2020:Preprint. doi: https://doi.org/10.1101/2020.04.07.20056440
  6. Official website of Moscow Mayor of Sergey Sobyanin [Electronic resource]. Available from: https://www.sobyanin.ru/podtverzhden-sluchai-novoi-koronavirusnoi-infektsii
  7. Стопкоронавирус.рф — официальный интернет-ресурс для информирования населения по вопросам коронавируса (COVID-19) [Электронный ресурс]. Available from: https://стопкоронавирус.рф.
  8. Luke TC, Kilbane EM, Jackson JL, Hoffman SL. Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment? Ann Intern Med. 2006;145(8):599–609. doi: https://doi.org/10.7326/0003-4819-145-8-200610170-00139
  9. Mair-Jenkins J, Saavedra-Campos M, Baillie JK, et al. The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis. J Infect Dis. 2015;211(1):80–90. doi: https://doi.org/10.1093/infdis/jiu396
  10. Cheng Y, Wong R, Soo Y, et al. Use of convalescent plasma therapy in SARS patients in Hong Kong. Eur J Clin Microbiol Infect Dis. 2005;24(1):44–46. doi: https://doi.org/10.1007/s10096-004-1271-9
  11. Sullivan HC, Roback JD. Convalescent Plasma: Therapeutic Hope or Hopeless Strategy in the SARS-CoV-2 Pandemic. Transfus Med Rev. 2020;34(3):145–150. doi: https://doi.org/ 10.1016/j.tmrv.2020.04.001
  12. Chen L, Xiong J, Bao L, Shi Y. Convalescent plasma as a potential therapy for COVID-19. Lancet Infect Dis. 2020;20(4):398–400. doi: https://doi.org/10.1016/S1473-3099(20)30141-9
  13. Dzik S. COVID-19 Convalescent Plasma: Now Is the Time for Better Science. Transfus Med Rev. 2020;34(3):141–144. doi: https://doi.org/10.1016/j.tmrv.2020.04.002
  14. Epstein J, Burnouf T. Points to consider in the preparation and transfusion of COVID-19 convalescent plasma. Vox Sang. 2020;115(6):485–487. doi: https://doi.org/10.1111/vox.12939
  15. Tiberghien P, de Lamballerie X, Morel P, et al. Collecting and evaluating convalescent plasma for COVID-19 treatment: why and how? Vox Sang. 2020;115(6):488–494. doi: https://doi.org/10.1111/vox.12926
  16. Joyner M, Wright RS, Fairweather D, et al. Early Safety Indicators of COVID-19 Convalescent Plasma in 5,000 Patients. Med Rxiv. 2020:Preprint. doi: https://doi.org/10.1101/2020.05.12.20099879
  17. Thompson C, Grayson N, Paton R. et al. Neutralising antibodies to SARS coronavirus 2 in Scottish blood donors — a pilot study of the value of serology to determine population exposure. 2020:Preprint. Med Rxiv. doi: https://doi.org/10.1101/2020.04.13.20060467
  18. Randomised Evaluation of COVID-19 Therapy (RECOVERY). 2020. Oxford, United Kingdom [Electronic resource]. Available from: https://www.recoverytrial.net/
  19. U.S. Food and Drug Administration. Recommendations for Investigational COVID-19 Convalescent Plasma. May 1, 2020 [Electronic resource]. Available from: https://www.fda.gov/vaccines-blood-biologics/investigational-new-drug-ind-or-device-exemption-ide-process-cber/recommendations-investigational-covid-19-convalescent-plasma
  20. Joyner MJ, Bruno KA, Klassen SA, et al. Mayo Clinical Protocol. 2020; 95. Safety Update: COVID-19 Convalescent Plasma in 20,000 Hospitalized Patients. Mayo Clin Proc. 2020;95(9):1888–1897. doi: https://doi.org/10.1016/j.mayocp.2020.06.028
  21. Инструкция по иммунизации доноров стафилококковым анатоксином и проведению плазмафереза для получения антистафилококковой плазмы. Утверждена заместителем Министра здравоохранения СССР 2 августа 1977 г. № 10-8/49. [Instrukciya po immunizacii donorov stafilokokkovym anatoksinom i provedeniyu plazmafereza dlya polucheniya antistafilokokkovoj plazmy. Utverzhdena zamestitelem Ministra zdravoohraneniya SSSR 2 avgusta 1977 g. № 10-8/49. (In Russ.)]
  22. Хватов В.Б. Иммунопрофилактика и иммунотерапия // Профилактика внутрибольничной инфекции. Руководство для врачей / под ред. Е.Н. Семиной, А.С. Ковалевой. — М.: Рапор, 1993. — 307 с. [Hvatov VB. Immunoprofilaktika i immunoterapiya. Profilaktika vnutribol’nichnoj infekcii. Rukovodstvo dlya vrachej. pod red. E.N. Seminoj, A.S. Kovalevoj. Moscow: Rapor; 1993. 307 p. (In Russ.)]
  23. Бодрова Г.Н. Получение и оценка иммунологической активности антитоксической антисинегнойной плазмы: автореф. дис. … канд. мед. наук. — М., 1997. [Bodrova GN. Poluchenie i ocenka immunologicheskoj aktivnosti antitoksicheskoj antisinegnojnoj plazmy: dis. … kand. med. nauk. Moscow; 1997. (In Russ.)]
  24. Булава Г.В. Иммунопрофилактика и иммунотерапия гнойно-септических осложнений у пострадавших с проникающими ранениями груди и живота: автореф. дис. … д-ра мед. наук. — М., 2003. [Bulava GV. Immunoprofilaktika i immunoterapiya gnojno-septicheskih oslozhnenij u postradavshih s pronikayushchimi raneniyami grudi i zhivota: avtoref. dis. … d-ra med. nauk. Moscow; 2003. (In Russ.)]
  25. Биткова Е.Е. Оценка специфической антимикробной активности иммунных плазм: автореф. дис. … канд. мед. наук. — М., 2007. [Bitkova EE. Ocenka specificheskoj antimikrobnoj aktivnosti immunnyh plazm: avtoref. dis. … kand. med. nauk. Moscow; 2007. (In Russ.)]
  26. Li L, Zhang W, Hu Y, et al. Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients with Severe and Life-threatening COVID-19: A Randomized Clinical Trial. JAMA. 2020;324(5):460–470. doi: https://doi.org/10.1001/jama.2020.10044
  27. Duan K, Liu B, Li C, et al. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proc Natl Acad Sci USA. 2020;117(17):9490–9496. doi: https://doi.org/10.1073/pnas.2004168117
  28. Zhang B, Liu S, Tan T, et al. Treatment with Convalescent Plasma for Critically Ill Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection. Chest. 2020;158(1):e9–e13. doi: https://doi.org/10.1016/j.chest.2020.03.039
  29. Ahn JY, Sohn Y, Lee SH, et al. Use of Convalescent Plasma Therapy in Two COVID-19 Patients with Acute Respiratory Distress Syndrome in Korea. J Korean Med Sci. 2020;35(14):e149. doi: https://doi.org/10.3346/jkms.2020.35.e14
  30. Shen C, Wang Z, Zhao F, et al. Treatment of 5 Critically Ill Patients with COVID-19 with Convalescent Plasma. JAMA. 2020;323(16):1582–1589. doi: https://doi.org/10.1001/jama.2020.4783
  31. Shang J, Ye G, Shi K, et al. Structural basis of receptor recognition by SARS-CoV-2. Nature. 2020;581(7807):221–224. doi: https://doi.org/10.1038/s41586-020-2179-y
  32. Worldometer Licensing is a provider of global COVID-19 [Electronic resource]. Available from: https://www.worldometers.info/coronavirus/
  33. EU CCP database — Covid-19 convalescent plasma collection and transfusion in the EU. Available from: https://ec.europa.eu/health/blood_tissues_organs/covid-19_en
  34. An EU programme of COVID-19 convalescent plasma collection and transfusion. Available from: https://ec.europa.eu/health/sites/health/files/blood_tissues_organs/docs/guidance_plasma_covid19_en.pdf
  35. Young MK. The indications and safety of polyvalent immunoglobulin for post-exposure prophylaxis of hepatitis A, rubella and measles. Hum Vaccin Immunother. 2019;15(9):2060–2065. doi: https://doi.org/10.1080/21645515.2019.1621148
  36. Gonik B. Passive immunization: the forgotten arm of immunologically based strategies for disease containment. Am J Obstet Gynecol. 2011;205(5):444.e1–444.e6. doi: https://doi.org/10.1016/j.ajog.2011.06.076.

Supplementary files

Supplementary Files Action
1.
Fig. The distribution of donors depending on the titer of the virus trailing antibodies in blood plasma. VNA - virus neutralization antibodies.

Download (75KB) Indexing metadata

Statistics

Views

Abstract - 554

PDF (Russian) - 2

Cited-By


Article Metrics

Metrics Loading ...

PlumX

Dimensions



Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies